<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02641587</url>
  </required_header>
  <id_info>
    <org_study_id>P2R-REXA-07-EU</org_study_id>
    <nct_id>NCT02641587</nct_id>
  </id_info>
  <brief_title>Reduced Exposure Study Using the CHTP 1.2 With 5 Days in a Confinement Setting Followed by 85 Days in an Ambulatory Setting.</brief_title>
  <official_title>A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.2 (CHTP 1.2), Compared to Continuing to Use Combustible Cigarettes, for 5 Days in Confinement Followed by 85 Days in an Ambulatory Setting.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Philip Morris Products S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Philip Morris Products S.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of the study is to demonstrate reduction in the levels of biomarkers of
      exposure (BoExp) to selected harmful and potentially harmful constituents (HPHCs) identified
      in cigarettes and to obtain safety information in healthy adult smokers switching to the
      Carbon Heated Tobacco Product 1.2 (CHTP 1.2) as compared to subjects continuing smoking
      cigarettes (CC) in a confinement setting for 5 days (exclusive use) followed by an ambulatory
      setting of 85 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">July 2017</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Concentrations of Monohydroxybutenylmercapturic Acid (MHBMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentration of S-phenylmercapturic Acid (S-PMA)</measure>
    <time_frame>5 days</time_frame>
    <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Levels of Carboxyhemoglobin (COHb)</measure>
    <time_frame>5 days</time_frame>
    <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)</measure>
    <time_frame>90 days</time_frame>
    <description>Concentrations measured at Day 90 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 90 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">121</enrollment>
  <condition>Smoking</condition>
  <arm_group>
    <arm_group_label>CHTP 1.2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ad libitum use of the CHTP 1.2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CC</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ad libitum use of subject's own preferred non-menthol brand of CC</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CHTP 1.2</intervention_name>
    <description>Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
    <arm_group_label>CHTP 1.2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CC</intervention_name>
    <description>Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
    <arm_group_label>CC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is aged ≥ 28 years.

          -  Subject is Caucasian.

          -  Subject is healthy, as judged by the Investigator.

          -  Subject has smoked at least 10 commercially available non-menthol CCs per day (no
             brand restrictions) at least for the last 6 weeks prior to the screening visit and
             admission.

          -  Subject has smoked at least for the last 10 years.

          -  Subject does not plan to quit smoking in the next 6 months.

        Exclusion Criteria:

          -  As per Investigator judgment, the subject cannot participate in the study for any
             reason (e.g., medical, psychiatric, and/or social reason).

          -  Subject has received medication within 14 days or within 5 half-lives of the
             medication (whichever is longer), which has an impact on cytochrome P450 1A2 (CYP1A2)
             or cytochrome P450 2A6 (CYP2A6) activity.

          -  Female subject is pregnant or breast feeding.

          -  Female subject does not agree to use an acceptable method of effective contraception.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>28 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christelle Haziza, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Philip Morris Products S.A.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monika Tomaszewska-Kiecana, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BioVirtus Research Site</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>BioVirtus Research Site Sp. z o.o.</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>December 23, 2015</study_first_submitted>
  <study_first_submitted_qc>December 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 29, 2015</study_first_posted>
  <results_first_submitted>October 2, 2018</results_first_submitted>
  <results_first_submitted_qc>March 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">March 6, 2019</results_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Smoking</keyword>
  <keyword>Cigarettes</keyword>
  <keyword>Reduced exposure</keyword>
  <keyword>Confinement</keyword>
  <keyword>Ambulatory</keyword>
  <keyword>Carbon Heated Tobacco Product</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 5, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02641587/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/87/NCT02641587/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Following enrollment of 121 subjects, each subject received a product test of CHTP 1.2 prior to randomization.
One subject was not randomized due to the physician's decision. This subject is included in the &quot;Exposed Not Randomized&quot; reporting group of the Baseline Characteristics.
Consequently, 120 subjects were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CHTP 1.2</title>
          <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
        </group>
        <group group_id="P2">
          <title>Cigarettes (CC)</title>
          <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Confinement Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="80"/>
                <participants group_id="P2" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Ambulatory Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Overall safety population refers to all subjects who were exposed and randomized or exposed and not randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>CHTP 1.2</title>
          <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
        </group>
        <group group_id="B2">
          <title>Cigarettes (CC)</title>
          <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
        </group>
        <group group_id="B3">
          <title>Exposed Not Randomized</title>
          <description>“Exposed not randomized” refers to all subjects exposed to CHTP 1.2 but not randomized.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="80"/>
            <count group_id="B2" value="40"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="121"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.9" spread="8.9"/>
                    <measurement group_id="B2" value="39.0" spread="8.0"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="38.8" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="40"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="120"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.74" spread="3.51"/>
                    <measurement group_id="B2" value="25.70" spread="2.96"/>
                    <measurement group_id="B3" value="21.7"/>
                    <measurement group_id="B4" value="25.69" spread="3.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Monohydroxybutenylmercapturic Acid (MHBMA)</title>
        <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
        <time_frame>5 days</time_frame>
        <population>Per Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.2</title>
            <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
          <group group_id="O2">
            <title>Cigarettes (CC)</title>
            <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Monohydroxybutenylmercapturic Acid (MHBMA)</title>
          <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
          <population>Per Protocol (PP) population</population>
          <units>pg/mg creat</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="285.5" lower_limit="258.0" upper_limit="315.8"/>
                    <measurement group_id="O2" value="1904" lower_limit="1641" upper_limit="2209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis will be conducted on the natural log scale. The Day 5 levels of MHBMA will be analyzed by means of a generalized linear model using randomized arm as covariate adjusting for sex, average cigarette consumption over the previous 6 weeks prior to Admission (value at Admission for stratification), and log-transformed baseline value of MHBMA.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The analysis will test if the geometric LS mean level of MHBMA for CHTP is lower than for CC. The following hypothesis will be evaluated:
H0: XCHTP - XCC ≤ 0.0
HA: XCHTP - XCC &gt; 0.0
where XCHTP and XCC are the geometric LS means of CHTP and CC, respectively. H0 is rejected with a type I error α = 2.5% (one-sided test).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints will be tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>Generalized linear model</method>
            <param_type>LS Mean Reduction</param_type>
            <param_value>85.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>82.06</ci_lower_limit>
            <ci_upper_limit>87.47</ci_upper_limit>
            <estimate_desc>Least squares (LS) means and estimate of the difference, and 95% CI will be back-transformed for obtaining geometric LS means for each arm, the reduction (calculated as 100% - ratio of CHTP 1.2 : CC [%]), and their 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</title>
        <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
        <time_frame>5 days</time_frame>
        <population>Per Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.2</title>
            <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
          <group group_id="O2">
            <title>Cigarettes (CC)</title>
            <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of 3-hydroxypropylmercapturic Acid (3-HPMA)</title>
          <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
          <population>Per Protocol (PP) population</population>
          <units>ng/mg creat</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="616.8" lower_limit="565.6" upper_limit="672.8"/>
                    <measurement group_id="O2" value="1031" lower_limit="907.9" upper_limit="1172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis will be conducted on the natural log scale. The Day 5 levels of 3-HPMA will be analyzed by means of a generalized linear model using randomized arm as covariate adjusting for sex, average cigarette consumption over the previous 6 weeks prior to Admission (value at Admission for stratification), and log-transformed baseline value of 3-HPMA.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The analysis will test if the geometric LS mean level of 3-HPMA for CHTP is lower than for CC. The following hypothesis will be evaluated:
H0: XCHTP - XCC ≤ 0.0
HA: XCHTP - XCC &gt; 0.0
where XCHTP and XCC are the geometric LS means of CHTP and CC, respectively. H0 is rejected with a type I error α = 2.5% (one-sided test).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints will be tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>Generalized linear model</method>
            <param_type>LS Mean Reduction</param_type>
            <param_value>40.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>30.25</ci_lower_limit>
            <ci_upper_limit>48.73</ci_upper_limit>
            <estimate_desc>Least squares (LS) means and estimate of the difference, and 95% CI will be back-transformed for obtaining geometric LS means for each arm, the reduction (calculated as 100% - ratio of CHTP 1.2 : CC [%]), and their 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentration of S-phenylmercapturic Acid (S-PMA)</title>
        <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
        <time_frame>5 days</time_frame>
        <population>Per Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.2</title>
            <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
          <group group_id="O2">
            <title>Cigarettes (CC)</title>
            <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentration of S-phenylmercapturic Acid (S-PMA)</title>
          <description>Concentrations measured at Day 5 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
          <population>Per Protocol (PP) population</population>
          <units>pg/mg creat</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="74"/>
                <count group_id="O2" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="386.6" lower_limit="358.7" upper_limit="416.7"/>
                    <measurement group_id="O2" value="2401" lower_limit="2151" upper_limit="2681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis will be conducted on the natural log scale. The Day 5 levels of S-PMA will be analyzed by means of a generalized linear model using randomized arm as covariate adjusting for sex, average cigarette consumption over the previous 6 weeks prior to Admission (value at Admission for stratification), and log-transformed baseline value of S-PMA.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The analysis will test if the geometric LS mean level of S-PMA for CHTP is lower than for CC. The following hypothesis will be evaluated:
H0: XCHTP - XCC ≤ 0.0
HA: XCHTP - XCC &gt; 0.0
where XCHTP and XCC are the geometric LS means of CHTP and CC, respectively. H0 is rejected with a type I error α = 2.5% (one-sided test).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints will be tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>Generalized linear model</method>
            <param_type>LS Mean Reduction</param_type>
            <param_value>83.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>81.61</ci_lower_limit>
            <ci_upper_limit>85.90</ci_upper_limit>
            <estimate_desc>Least squares (LS) means and estimate of the difference, and 95% CI will be back-transformed for obtaining geometric LS means for each arm, the reduction (calculated as 100% - ratio of CHTP 1.2 : CC [%]), and their 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Levels of Carboxyhemoglobin (COHb)</title>
        <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
        <time_frame>5 days</time_frame>
        <population>Per Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.2</title>
            <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
          <group group_id="O2">
            <title>Cigarettes (CC)</title>
            <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Levels of Carboxyhemoglobin (COHb)</title>
          <description>% COHb blood measurements performed in the evening of Day 5, expressed as % of saturation of hemoglobin.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 5 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
          <population>Per Protocol (PP) population</population>
          <units>% of saturation of hemoglobin</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" lower_limit="1.86" upper_limit="2.16"/>
                    <measurement group_id="O2" value="4.53" lower_limit="4.01" upper_limit="5.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis will be conducted on the natural log scale. The Day 5 levels of COHb will be analyzed by means of a generalized linear model using randomized arm as covariate adjusting for sex, average cigarette consumption over the previous 6 weeks prior to Admission (value at Admission for stratification), and log-transformed baseline value of COHb.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The analysis will test if the geometric LS mean level of COHb for CHTP is lower than for CC. The following hypothesis will be evaluated:
H0: XCHTP - XCC ≤ 0.0
HA: XCHTP - XCC &gt; 0.0
where XCHTP and XCC are the geometric LS means of CHTP and CC, respectively. H0 is rejected with a type I error α = 2.5% (one-sided test).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints will be tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>Generalized linear model</method>
            <param_type>LS Mean Reduction</param_type>
            <param_value>55.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>49.03</ci_lower_limit>
            <ci_upper_limit>61.56</ci_upper_limit>
            <estimate_desc>Least squares (LS) means and estimate of the difference, and 95% CI will be back-transformed for obtaining geometric LS means for each arm, the reduction (calculated as 100% - ratio of CHTP 1.2 : CC [%]), and their 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)</title>
        <description>Concentrations measured at Day 90 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 90 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
        <time_frame>90 days</time_frame>
        <population>Per Protocol (PP) population</population>
        <group_list>
          <group group_id="O1">
            <title>CHTP 1.2</title>
            <description>Ad libitum use of the CHTP 1.2
CHTP 1.2: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
          <group group_id="O2">
            <title>Cigarettes (CC)</title>
            <description>Ad libitum use of subject's own preferred non-menthol brand of CC
CC: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.</description>
          </group>
        </group_list>
        <measure>
          <title>Concentrations of Total 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (Total NNAL)</title>
          <description>Concentrations measured at Day 90 in urine, adjusted for creatinine.
Geometric least squares (LS) means and confidence intervals (Cls) from a generalized linear model conducted on log-transformed Day 90 values with log-transformed baseline value, study arm, sex and CC consumption reported at admission as fixed effect factors.</description>
          <population>Per Protocol (PP) population</population>
          <units>pg/mg creat</units>
          <param>Geometric Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.26" lower_limit="31.39" upper_limit="44.24"/>
                    <measurement group_id="O2" value="180.6" lower_limit="144.8" upper_limit="225.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis will be conducted on the natural log scale. The Day 5 levels of Total NNAL will be analyzed by means of a generalized linear model using randomized arm as covariate adjusting for sex, average cigarette consumption over the previous 6 weeks prior to Admission (value at Admission for stratification), and log-transformed baseline value of Total NNAL.</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>The analysis will test if the geometric LS mean level of Total NNAL for CHTP is lower than for CC. The following hypothesis will be evaluated:
H0: XCHTP - XCC ≤ 0.0
HA: XCHTP - XCC &gt; 0.0
where XCHTP and XCC are the geometric LS means of CHTP and CC, respectively. H0 is rejected with a type I error α = 2.5% (one-sided test).</non_inferiority_desc>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The primary endpoints will be tested using a multiple testing procedure to preserve the overall alpha level by simultaneously testing the endpoints using a closed procedure with each test performed at an alpha level of 2.5% one sided.</p_value_desc>
            <method>Generalized linear model</method>
            <param_type>LS Mean Reduction</param_type>
            <param_value>79.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>72.73</ci_lower_limit>
            <ci_upper_limit>84.39</ci_upper_limit>
            <estimate_desc>Least squares (LS) means and estimate of the difference, and 95% CI will be back-transformed for obtaining geometric LS means for each arm, the reduction (calculated as 100% - ratio of CHTP 1.2 : CC [%]), and their 95% CI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the signature of the Informed Consent Form (ICF) until the end of the safety follow-up period, which covered a period of between 128 to 169 days for each subject.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Product Test</title>
          <description>After all inclusion/exclusion criteria were checked, all eligible subjects were enrolled and performed a product test using up to five CHTP 1.2</description>
        </group>
        <group group_id="E2">
          <title>CHTP 1.2 Confinement</title>
          <description>Ad libitum use of the CHTP 1.2 for 5 days in confinement.</description>
        </group>
        <group group_id="E3">
          <title>CC Confinement</title>
          <description>Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement.</description>
        </group>
        <group group_id="E4">
          <title>CHTP 1.2 Ambulatory</title>
          <description>Ad libitum use of the CHTP 1.2 for 85 days in an ambulatory setting.</description>
        </group>
        <group group_id="E5">
          <title>CC Ambulatory</title>
          <description>Ad libitum use of subject's own preferred non-menthol brand of CC for 85 days in an ambulatory setting.</description>
        </group>
        <group group_id="E6">
          <title>CHTP 1.2 Safety FU</title>
          <description>CHTP 1.2 Safety Follow-Up period of 28 days</description>
        </group>
        <group group_id="E7">
          <title>CC Safety FU</title>
          <description>CC Safety Follow-Up period of 28 days</description>
        </group>
        <group group_id="E8">
          <title>CHTP 1.2 Post-Randomization</title>
          <description>CHTP 1.2 Post-Randomization period</description>
        </group>
        <group group_id="E9">
          <title>CC Post-Randomization</title>
          <description>CC Post-Randomization period</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Peritonsillar Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="62" subjects_at_risk="121"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="80"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="40"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="77"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="64" subjects_at_risk="80"/>
                <counts group_id="E9" subjects_affected="31" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="121"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="6" subjects_affected="6" subjects_at_risk="77"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="3" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="15" subjects_affected="12" subjects_at_risk="80"/>
                <counts group_id="E9" events="7" subjects_affected="5" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel Puncture Site Bruise</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>General disorders</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="121"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="7" subjects_affected="7" subjects_at_risk="80"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="121"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="9" subjects_affected="9" subjects_at_risk="77"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="15" subjects_affected="14" subjects_at_risk="80"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="77"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Blood Triglycerides Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="80"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="17" subjects_affected="15" subjects_at_risk="80"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="121"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="80"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="54" subjects_affected="42" subjects_at_risk="121"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="80"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="40"/>
                <counts group_id="E4" events="15" subjects_affected="14" subjects_at_risk="77"/>
                <counts group_id="E5" events="9" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="25" subjects_affected="20" subjects_at_risk="80"/>
                <counts group_id="E9" events="16" subjects_affected="11" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="121"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="80"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="40"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="77"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="40"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="77"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="40"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="121"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="80"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="77"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="80"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="40"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="80"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="40"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>We confirm we have the contractual provisions in place which specify that in no event will the study site be allowed to disclose to any third party (or publicly release) any information obtained through the study without the CRO's prior written consent which in turn cannot provide such consent without Sponsor's approval unless such publication is made to satisfy regulatory requirements.
The Intellectual Property rights and research results from the present study belong to the Sponsor.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christelle Haziza</name_or_title>
      <organization>Philip Morris Products S.A.</organization>
      <phone>+41 58 242 11 11</phone>
      <email>christelle.haziza@pmi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

